Key Highlights
- Steven Evans, Ph.D., appointed as Chief Scientific Officer and Senior Vice President of R&D at Nature’s Toolbox (NTx).
- Brings a wealth of experience in drug development strategy and scientific leadership from his tenure at Pfizer and GSK.
- NTx recently secured $47.5M in Series B financing, marking a significant phase of growth and innovation.
Source: Business Wire
Notable Quotes
- “We are grateful for his leadership and his significant contributions to the company’s success. As we take our company to the next level, we are excited to welcome Steve to the leadership team.” – Jamie Coffin, CEO at NTx
- “NTx has pioneered a platform that stands to revolutionize the field of drug discovery and development…” – Steven Evans, Ph.D., Chief Scientific Officer at NTx
SoHC's Take
Nature’s Toolbox, Inc. (NTx), a pioneering life sciences company, has just announced the strategic appointment of Steven Evans, Ph.D., as its new Chief Scientific Officer and Senior Vice President of R&D. With an illustrious career at global pharmaceutical leaders like Pfizer and GSK, Evans is set to bring a rich repertoire of drug development strategy, knowledge, and scientific leadership to NTx. His appointment comes at a crucial time following NTx’s impressive $47.5M Series B financing round and a period of significant technological advancements and growth spearheaded by the company’s founder, Alex Koglin.
Evans’s expertise in translational pharmacology and immunology, coupled with his proven track record in leading drug development from discovery through to clinical phases, positions him uniquely to drive NTx’s R&D initiatives. His leadership is expected to leverage the company’s innovative NTxpress® and NTxscribe® systems, which promise to revolutionize the manufacturing of mRNA vaccines and protein therapeutics in an eco-friendly and scalable manner.
This strategic appointment signifies NTx’s commitment to accelerating its research and development efforts, underscoring the company’s dedication to advancing healthcare through innovative biomanufacturing solutions. Evans’s role will be pivotal in furthering NTx’s mission to deliver sustainable, scalable, and cost-effective health solutions to the market, ensuring a brighter future for global healthcare.
